UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma

PloS one, 2013-10, Vol.8 (10), p.e78649

2013

Volltextzugriff (PDF)

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-05, Vol.23 (2), p.133-138

2024

Volltextzugriff (PDF)

KRAS-mutated non-small cell lung cancer: new therapy strategies

Sibirskiĭ onkologicheskiĭ zhurnal, 2024-05, Vol.23 (2), p.72-81

2024

Volltextzugriff (PDF)

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2019-12 (19), p.16-21

2019

Volltextzugriff (PDF)

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Medicinskij sovet, 2021-12 (20), p.62-67

2021

Volltextzugriff (PDF)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Frontiers in oncology, 2021-07, Vol.11, p.709877-709877

2021

Volltextzugriff (PDF)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1986-1991

2023

Volltextzugriff (PDF)

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

Annals of oncology, 2019-04, Vol.30, p.i38-i38

2019

Volltextzugriff (PDF)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma

Medicinskij sovet, 2022-06 (9), p.157-162

2022

Volltextzugriff (PDF)

Adjuvant immunotherapy of operable non-small cell lung cancer: achievements and treatment prospects

Medicinskij sovet, 2022-06 (9), p.14-20

2022

Volltextzugriff (PDF)

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

Sibirskiĭ onkologicheskiĭ zhurnal, 2023-05, Vol.22 (2), p.56-64

2023

Volltextzugriff (PDF)

Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA

Annals of oncology, 2017-10, Vol.28, p.vii8-vii8

2017

Volltextzugriff (PDF)

Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas

BMC cancer, 2014-02, Vol.14 (1), p.100-100, Article 100

2014

Volltextzugriff (PDF)

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

Medicinskij sovet, 2019-12 (19), p.30-36

2019

Volltextzugriff (PDF)

Рembrolizumab as second line therapy for hepatocellular patient

Medicinskij sovet, 2021-12 (20), p.150-154

2021

Volltextzugriff (PDF)

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Medical Council, 2018-07 (10), p.9-10

2018

Volltextzugriff (PDF)

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2021-08 (9), p.18-24

2021

Volltextzugriff (PDF)

Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

Annals of oncology, 2019-04, Vol.30, p.ii48-ii49

2019

Volltextzugriff (PDF)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Medicinskij sovet, 2019-06 (10), p.110-114

2019

Volltextzugriff (PDF)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

Medicinskij sovet, 2019-06 (10), p.37-41

2019

Volltextzugriff (PDF)

Long-term disease control in a patient with ALK-positive non-small cell lung cancer

Medicinskij sovet, 2022-06 (9), p.172-177

2022

Volltextzugriff (PDF)

Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer

Sibirskiĭ onkologicheskiĭ zhurnal, 2022-03, Vol.21 (1), p.115-121

2022

Volltextzugriff (PDF)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Medicinskij sovet, 2020-12 (20), p.194-198

2020

Volltextzugriff (PDF)

Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer

Medical Council, 2018-11 (19), p.122-125

2018

Volltextzugriff (PDF)

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

Medicinskij sovet, 2020-07 (9), p.190-195

2020

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(269)
Mit Volltextzugriff
(144)

Publikationsform

Artikel
(294)
Tagungsberichte
(1)

Sprache

Englisch
(243)
Russisch
(87)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

KRAS-mutated non-small cell lung cancer: new therapy strategies

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma

Adjuvant immunotherapy of operable non-small cell lung cancer: achievements and treatment prospects

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA

Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

Рembrolizumab as second line therapy for hepatocellular patient

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

Long-term disease control in a patient with ALK-positive non-small cell lung cancer

Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Intermediate results of combination therapy in patients with oligometastatic non-small cell lung cancer

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

Suchergebnisse filtern